Rapport Therapeutics (NASDAQ:RAPP) Trading Down 5.7% – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP) fell 5.7% on Thursday . The company traded as low as $19.10 and last traded at $19.10. 3,520 shares were traded during mid-day trading, a decline of 98% from the average session volume of 153,359 shares. The stock had previously closed at $20.25.

Rapport Therapeutics Price Performance

The firm has a fifty day simple moving average of $23.18.

Institutional Investors Weigh In On Rapport Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at approximately $2,716,000. Perceptive Advisors LLC bought a new stake in Rapport Therapeutics in the second quarter worth approximately $17,403,000. ARCH Venture Management LLC acquired a new position in shares of Rapport Therapeutics during the 2nd quarter worth $86,730,000. TD Asset Management Inc bought a new position in shares of Rapport Therapeutics during the 2nd quarter valued at $2,361,000. Finally, Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at $58,105,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.